biote Corp. (BTMD)
biote Corp. (BTMD) Stock Price, Analysis & Data
| Bid | 1.62 |
| Market Cap | 51.55M |
| Revenue (ttm) | 183.53M |
| Net Income (ttm) | 5.86M |
| Beta | 1.65 |
| EPS (ttm) | 0.14 |
| PE Ratio (ttm) | 10.36 |
| Forward PE | 3.22 |
| P/B (ttm) | -0.63 |
| P/S (ttm) | 0.28 |
| Earnings Date | Nov 4, 2026 |
| Ask | 2.9 |
| Volume | 73,524 |
| Avg. Volume (20D) | 286,637 |
| Open | 1.55 |
| Previous Close | 1.54 |
| Day's Range | 1.44 - 1.55 |
| 52-Week Range | 1.27 - 3.62 |
| Analyst | Strong Buy |
| Price Target | 2.5 (72.41%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BTMD
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the h...
Financial Performance
In 2025, biote's revenue was 192.22M, a decrease of -2.52% compared to the previous year's 197.19M. Earnings were 27.05M, an increase of 756.67%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for BTMD stock is "Strong Buy". The 12-month stock price forecast is 2.5, which is upside of 72.41% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
